Voltar
Revisão Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

2018; Adis, Springer Healthcare; Volume: 32; Issue: 6 Linguagem: Inglês

10.1007/s40259-018-0322-1

ISSN

1179-190X

Autores

Wânia Cristina da Silva, Vânia Eloísa de Araújo, Ellias Magalhães e Abreu Lima, Jéssica Barreto Ribeiro dos Santos, Michael Ruberson Ribeiro da Silva, Paulo Henrique Ribeiro Fernandes Almeida, Francisco de Assis Acúrcio, Brian Godman, Amanj Kurdi, Mariângela Leal Cherchiglia, Eli Iôla Gurgel Andrade,

Tópico(s)

Cancer Treatment and Pharmacology

Resumo

The last decade has seen the increasing use of biological medicines in combination with chemotherapy containing 5-fluorouracil/oxaliplatin or irinotecan for the treatment of metastatic colorectal cancer (mCRC). These combinations have resulted in increased progression-free survival (PFS) in patients with mCRC; however, there are remaining concerns over the extent of their effect on overall survival (OS). Published studies to date suggest no major differences between the three currently available monoclonal antibodies (MoAbs); however, there are differences in costs. In addition, there is rising litigation in Brazil in order to access these medicines as they are currently not reimbursed.

Referência(s)